Pharmaceutical manufacturers of Glatiramer

Established in Darmstadt, Germany in 1668 by Friedrich Jacob Merck, Merck KGaA stands as the oldest pharmaceutical and chemical corporation globally. It is renowned for its pioneering and high-quality advanced products in the fields of healthcare, life science, and performance materials. Internationally, the company is recognized as Merck, while operating as EMD Serono in the Biopharma sector, as MilliporeSigma in the Life Science sector, and as EMD Performance Materials in the materials sector in the United States and Canada.

CordenPharma International, an all-encompassing CDMO for the worldwide market. Established as the global pharmaceutical service & production platform of International Chemical Investors Group in 2006, CordenPharma serves as your all-encompassing ally in the Contract Development & Manufacturing (CDMO) of APIs, Drug Products, and associated Packaging Services. With an expanding network of cGMP facilities throughout Europe and the US structured under five Technology Platforms – Peptides, Lipids & Carbohydrates - Highly Potent & Oncology - Injectables - Small Molecules - Antibiotics – CordenPharma specialists interpret intricate processes, concepts and ventures at any phase.

Founded in 1978, Biocon Limited is the largest biotechnology company in India and a leading company in Asia, focusing on biopharmaceuticals and research services. It is an integrated and innovation-driven enterprise that provides affordable solutions for chronic diseases globally. The company develops, manufactures, and offers a diverse portfolio of Small Molecules APIs & Formulations and Complex Biologics, including Novels and Biosimilars like MAbs, rh-insulin& Insulin Analogs. Among its notable products are the world's first Pichia-based recombinant human Insulin, INSUGEN, Glargine, BASALOG, and India's first biologic BioMAb-EGFR for head and neck cancer. Additionally, it has developed Itolizumab, a 'first in class' anti-CD6 monoclonal antibody, introduced as Alzumab for psoriasis in India in 2013.

Established in 1978 as a specialized facility for Small Volume Parenterals (SVPs), Gland Pharma has evolved into a forward-thinking and quality-focused organization catering to the pharmaceutical requirements of diverse global markets. The company possesses state-of-the-art facilities for injectables established in partnership with Vetter Group, Germany, providing Gland Pharma a technological advantage in injectables, particularly in Pre Filled Syringes.

Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 employees, Natco today has eight manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in New Drug Development, etc. Natco family currently consists of around 4500 employees, we are consistently ranked among fastest growing pharmaceutical companies in India. Natco is well recognized for its innovation in Pharmaceutical R&D.

USV is a 60-year-old organization headquartered in Mumbai, generating approximately US$ 500 million in revenue, primarily from the Diabetic and Cardiac sectors. It is one of the top 15 companies in India, operating in over 60 countries and serving more than 100 satisfied customers with exports totaling around US$ 100 million. With 100+ product approvals globally and 30+ DMF submissions worldwide, USV provides value-added products in Oral Solids, Injectables (PFS, Vials), Ophthalmics, Biosimilars (Pegfilgrastim), and Peptides.

Established in 2007 primarily as a company focused on research and development, Apothecon Pharmaceuticals in India has experienced continuous growth and currently specializes in the production of primary API drugs, their intermediates, and formulations. Our objective is to offer high-quality medications of outstanding quality on a global scale at reasonable prices. Our product range encompasses APIs in critical medical areas such as oncology, cardiology, antidotes, anesthetics, and orphan drugs, among others. Our facility has been examined and sanctioned by various regulatory bodies including the US FDA, UK MHRA, WHO GMP, State GMP, and the MOH in Turkey and Yemen. We serve clients worldwide.

Hybio operates as a pioneering technology company specializing in the research and development as well as the production of a wide range of peptide goods. Established in 1998, we have evolved into a prominent peptide pharmaceutical firm and the first to go public in China (2011, stock code 300199). Our offerings encompass a comprehensive selection of peptide products (Active Pharmaceutical Ingredients & Finished Dosage Forms) and solutions (Contract Research Organization & Contract Development and Manufacturing Organization). The primary market for our peptide Finished Dosage Forms is within China.

AmbioPharm, established in 2005 and based in North Augusta, South Carolina, USA, is a global peptide CDMO (Contract Development and Manufacturing Organization) that specializes in creating highly effective manufacturing procedures for peptide-based APIs at varying scales. The company runs two cGMP-compliant manufacturing sites, one in South Carolina, USA, and another in Shanghai, China. These facilities produce new chemical entities (NCEs) and generic peptide APIs for international clients. Both locations have undergone multiple FDA inspections with favorable results. AmbioPharm is capable of managing all forms of peptide manufacturing, from research to cGMP.